STAKEHOLDER EVENT ON BIOSIMILAR MEDICINAL PRODUCTS
BRUSSELS, 13 DECEMBER 2022
9H30 - 16H15 CET*

WEBEX PRE-REGISTRATION LINK

DRAFT AGENDA

09.00 – 09.30 **Registration and welcome**

09.30 – 09.40 **Introductory note**
- John Ryan, Acting Deputy Director General for Health, DG SANTE, European Commission

09.40 – 09.50 **How biosimilars impact my access to affordable medicines**
- Patient speaker

09.50 – 10.20 **The impact of biosimilar competition in Europe**
- Per Troein, VP, Strategic partners, IQVIA
- Max Newton, Global supplier & association relations, IQVIA

Interactive Q&A discussion with the audience

10.20 – 10.45 **Coffee & networking break**

10.45 – 12.30 **Interchangeability, switching and substitution of biosimilars:** scientific evidence, regulatory guidance and national policies

Chair: Harald Mische, Deputy Head of Unit for Medical Products, DG SANTE, European Commission

1) Interchangeability of biosimilars

Available evidence on interchangeability of biosimilars
- Liese Barbier, Postdoctoral Researcher Pharmaceutical Sciences, KU Leuven, Belgium

Joint EMA-HMA statement on interchangeability
- Steffen Thirstrup MD, Affiliate Professor and Chief Medical Officer at the European Medicines Agency (EMA)

Interactive Q&A discussion with the audience

2) National biosimilar policies: switching and substitution

- Sabine Vogler, Head of the Pharmacoeconomics Department at the Austrian National Public Health Institute, GÖG
- Olga Pitsillidou, Officer Health Insurance Organization (CY)

- Helga Festoy, Head of Unit Norwegian Medicines Agency (NO)
- Nadia Amer, Project Officer Health Products Department National Health Insurance Fund CNAM (FR)
- Bente Glintborg, Senior rheumatologist and head of the DANBIO steering committee (DK)

Interactive Q&A discussion with the audience

12.30 – 13.30 **Networking lunch**

13.30 – 14.40 **Building trust in oncology biosimilars:** clinical practice

Chair: Peter Schneider, Health Expert at the Austrian National Public Health Institute, GÖG (AT)

Improving biosimilar access to the benefit of patients
- Ward Rommel, Chair of ECL Access to Medicines Task Force, Expert in Cancer Care at Kom op tegen kanker

Perspective from an oncology clinician
- Dr. Rosa Giuliani, Director of Public Policy at the European Society for Medical Oncology (ESMO)

The role of pharmacists in oncology biosimilar treatment
- Dr. Tilman Schöning, Deputy Head of Pharmacy Heidelberg University Hospital, Member of the European Society of Oncology Pharmacy (ESOP)

The role of nurses in switch management between similar biological medicines
- Dr. Adriano Friganovic, President of the European Specialist Nurses Organisation (ESNO) and World Federation of Critical Care Nurses (WFCCN)

Interactive Q&A discussion with the audience

14.40 – 15.00 **Coffee & networking break**

15.00 – 16.00 **Untapping the full potential of biosimilars**

Chair: Sanja Matic, Head of Department for utilisation and prices of medicines, HALMED (HR)

<u>Interactive panel discussion</u>
- Simone Boselli, Public Affairs Director, EURORDIS-Rare Diseases Europe
- Yannis Natsis, Director of the European Social Insurance Platform (ESIP)
- Julie Maréchal-Jamil, Director Biosimilar Policy & Science, Medicines for Europe
- Dr. Rosa Giuliani, Director of Public Policy at the European Society for Medical Oncology (ESMO)

- Despoina Makridaki, Director of Pharmaceutical Services at the Sismanoglio-Amalia Fleming General Hospital of Attica, Member of the Board and Scientific Committee of the European Association of Hospital Pharmacists (EAHP)
- Ber Oomen, Executive Director of the European Specialist Nurses Organisation (ESNO)

16.00 - 16.15 **Closing words**

- DG SANTE

* * * * * *